Beta Drugs Limited — Change in Directors/KMP/SMP/Auditor/RTA

Beta Drugs Limited has informed the stock exchanges about a change in its key management personnel and statutory auditors. The company has appointed a new Chief Financial Officer (CFO) and a new statutory auditor to oversee its financial reporting and compliance. This move comes as part of the company's standard governance practice to ensure fresh oversight and expertise.

For investors, this is a routine administrative update that does not typically signal any operational shift. However, it is worth monitoring the company's future filings to ensure a smooth transition in financial reporting and governance standards. The market usually views such changes neutrally unless accompanied by other significant announcements.